2 Big Pharma Giants Headed in Opposite Directions
Earnings season's tearing through the health care sector, and Bristol-Myers Squibb and GlaxoSmithKline have faced off with investors this week. Bristol hit all the right points: The company saw its sales climb by 9% for the quarter, and drugs such as skin cancer treatment Yervoy are helping this big pharma staple overcome the residual effects of the patent cliff.
It's a different story for GlaxoSmithKline. The company's corruption probe in China has come back to haunt its finances. Glaxo's China sales dropped by more than 60% for the quarter, and the company's leadership isn't yet sure when the negative impact from China will end.
Where Bristol's stock has soared recently, Glaxo's shares haven't been able to generate much momentum. But where are these two big pharma giants headed in the near future? In the video below, Fool contributor Dan Carroll takes you through Bristol-Myers Squibb's and GlaxoSmithKline's third quarter takeaways and whether either of these stocks is worth your investment heading forward.
More dividend ideas
Big pharma stocks like Glaxo and Bristol have long been strong picks for any dividend investor, but are times changing on the markets? If you're an investor who prefers returns to rhetoric, you'll want to read The Motley Fool's new free report "5 Dividend Myths... Busted!" In it, you'll learn which stocks provide premium growth and whether bigger dividends are better. Click here to keep reading.
The article 2 Big Pharma Giants Headed in Opposite Directions originally appeared on Fool.com.Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.